WHAT AND WHERE IS HEAVEN?

Does heaven exist? With well over 100,000 plus recorded and described spiritual experiences collected over 15 years, to base the answer on, science can now categorically say yes. Furthermore, you can see the evidence for free on the website allaboutheaven.org.

Available on Amazon
https://www.amazon.com/dp/B086J9VKZD
also on all local Amazon sites, just change .com for the local version (.co.uk, .jp, .nl, .de, .fr etc.)

VISIONS AND HALLUCINATIONS

This book, which covers Visions and hallucinations, explains what causes them and summarises how many hallucinations have been caused by each event or activity. It also provides specific help with questions people have asked us, such as ‘Is my medication giving me hallucinations?’.

Available on Amazon
https://www.amazon.com/dp/B088GP64MW 
also on all local Amazon sites, just change .com for the local version (.co.uk, .jp, .nl, .de, .fr etc.)


Observations placeholder

Neurologic Adverse Events Associated with Voriconazole Therapy: Report of Two Pediatric Cases

Identifier

023028

Type of Spiritual Experience

Hallucination

Number of hallucinations: 2

Background

A description of the experience

Case Rep Infect Dis. 2016;2016:3989070. doi: 10.1155/2016/3989070. Epub 2016 May 24.  Neurologic Adverse Events Associated with Voriconazole Therapy: Report of Two Pediatric Cases. Demir SÖ1, Atici S1, Akkoç G1, Yakut N1, İkizoğlu NB2, Eralp EE2, Soysal A1, Bakir M1.

1Marmara University School of Medicine, Department of Pediatrics, Division of Pediatric Infectious Diseases, 34912 Istanbul, Turkey.

2Marmara University School of Medicine, Department of Pediatrics, Division of Pediatric Pulmonology, 34912 Istanbul, Turkey.

Although voriconazole, a triazole antifungal, is a safe drug, treatment with this agent is associated with certain adverse events such as

  • hepatic,
  • neurologic, and
  • visual disturbances.

The current report presents two cases, one a 9-year-old boy and the other a 17-year-old girl, who experienced neurologic side effects associated with voriconazole therapy.

Our aim is to remind readers of the side effects of voriconazole therapy in order to prevent unnecessary investigations especially for psychological and ophthalmologic problems.

The first case was a 9-year-old boy with cystic fibrosis and invasive aspergillosis that developed photophobia, altered color sensation, and fearful visual hallucination.

The second case was a 17-year-old girl with cystic fibrosis and allergic bronchopulmonary aspergillosis, and she experienced photophobia, fatigue, impaired concentration, and insomnia, when the dose of voriconazole therapy was increased from 12 mg/kg/day to 16 mg/kg/day.

The complaints of the two patients disappeared after discontinuation of voriconazole therapy. Our experience in these patients reminded us of the importance of being aware of the neurologic adverse events associated with voriconazole therapy in establishing early diagnosis and initiating prompt treatment.

In addition, although serum voriconazole concentration was not measured in the present cases, therapeutic drug monitoring for voriconazole seems to be critically important in preventing neurologic side effects in pediatric patients.

PMID: 27313918

The source of the experience

PubMed

Concepts, symbols and science items

Concepts

Symbols

Science Items

Activities and commonsteps

Commonsteps

References